Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1963 1
1965 1
1968 1
1970 2
1972 4
1974 1
1975 2
1976 3
1977 2
1978 4
1979 3
1980 3
1981 3
1982 5
1983 5
1984 1
1985 2
1986 3
1987 5
1988 2
1989 6
1990 4
1991 5
1992 5
1993 2
1994 6
1995 2
1996 1
1997 4
1998 1
1999 5
2000 7
2001 3
2002 3
2003 11
2004 5
2005 5
2006 6
2007 6
2008 6
2009 9
2010 7
2011 13
2012 17
2013 15
2014 19
2015 21
2016 31
2017 27
2018 25
2019 39
2020 30
2021 22
2022 22
2023 13

Text availability

Article attribute

Article type

Publication date

Search Results

407 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, Saito K, Kawaguchi Y, Kamio T, Kojima A, Sugihara M, Yamaguchi K; DESTINY-Gastric01 Investigators. Shitara K, et al. Among authors: iwasa s. N Engl J Med. 2020 Jun 18;382(25):2419-2430. doi: 10.1056/NEJMoa2004413. Epub 2020 May 29. N Engl J Med. 2020. PMID: 32469182 Clinical Trial.
Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Hashimoto H, Abe M, Tokuyama O, Mizutani H, Uchitomi Y, Yamaguchi T, Hoshina Y, Sakata Y, Takahashi TY, Nakashima K, Nakao M, Takei D, Zenda S, Mizukami K, Iwasa S, Sakurai M, Yamamoto N, Ohe Y. Hashimoto H, et al. Among authors: iwasa s. Lancet Oncol. 2020 Feb;21(2):242-249. doi: 10.1016/S1470-2045(19)30678-3. Epub 2019 Dec 11. Lancet Oncol. 2020. PMID: 31838011 Clinical Trial.
Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial.
Yamaguchi K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, Shimoyama T, Lee KW, Saito K, Kawaguchi Y, Kamio T, Kojima A, Sugihara M, Shitara K. Yamaguchi K, et al. Among authors: iwasa s. J Clin Oncol. 2023 Feb 1;41(4):816-825. doi: 10.1200/JCO.22.00575. Epub 2022 Nov 15. J Clin Oncol. 2023. PMID: 36379002 Free PMC article. Clinical Trial.
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.
Shitara K, Iwata H, Takahashi S, Tamura K, Park H, Modi S, Tsurutani J, Kadowaki S, Yamaguchi K, Iwasa S, Saito K, Fujisaki Y, Sugihara M, Shahidi J, Doi T. Shitara K, et al. Among authors: iwasa s. Lancet Oncol. 2019 Jun;20(6):827-836. doi: 10.1016/S1470-2045(19)30088-9. Epub 2019 Apr 29. Lancet Oncol. 2019. PMID: 31047804 Clinical Trial.
Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study.
Sunami K, Ichikawa H, Kubo T, Kato M, Fujiwara Y, Shimomura A, Koyama T, Kakishima H, Kitami M, Matsushita H, Furukawa E, Narushima D, Nagai M, Taniguchi H, Motoi N, Sekine S, Maeshima A, Mori T, Watanabe R, Yoshida M, Yoshida A, Yoshida H, Satomi K, Sukeda A, Hashimoto T, Shimizu T, Iwasa S, Yonemori K, Kato K, Morizane C, Ogawa C, Tanabe N, Sugano K, Hiraoka N, Tamura K, Yoshida T, Fujiwara Y, Ochiai A, Yamamoto N, Kohno T. Sunami K, et al. Among authors: iwasa s. Cancer Sci. 2019 Apr;110(4):1480-1490. doi: 10.1111/cas.13969. Epub 2019 Apr 2. Cancer Sci. 2019. PMID: 30742731 Free PMC article.
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS, Kim TW. Xu RH, et al. Among authors: iwasa s. Lancet Oncol. 2018 May;19(5):660-671. doi: 10.1016/S1470-2045(18)30140-2. Epub 2018 Mar 16. Lancet Oncol. 2018. PMID: 29555258 Clinical Trial.
Left atrial dissection.
Tsukui H, Iwasa S, Yamazaki K. Tsukui H, et al. Among authors: iwasa s. Gen Thorac Cardiovasc Surg. 2015 Aug;63(8):434-45. doi: 10.1007/s11748-015-0562-7. Epub 2015 May 24. Gen Thorac Cardiovasc Surg. 2015. PMID: 26003839 Review.
Decarboxylative Fluorination of 2-Pyridylacetates.
Kawanishi R, Phongphane L, Iwasa S, Shibatomi K. Kawanishi R, et al. Among authors: iwasa s. Chemistry. 2019 Jun 4;25(31):7453-7456. doi: 10.1002/chem.201900565. Epub 2019 Apr 26. Chemistry. 2019. PMID: 31026095
A heat-melt adhesive-assisted transferable electrode films.
Maruyama Y, Nagamine K, Iwasa S, Miyabo A, Tokito S. Maruyama Y, et al. Among authors: iwasa s. Sci Rep. 2021 Jan 8;11(1):36. doi: 10.1038/s41598-020-79504-7. Sci Rep. 2021. PMID: 33420083 Free PMC article.
Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial.
Yamada Y, Boku N, Mizusawa J, Iwasa S, Kadowaki S, Nakayama N, Azuma M, Sakamoto T, Shitara K, Tamura T, Chin K, Hata H, Nakamori M, Hara H, Yasui H, Katayama H, Fukuda H, Yoshikawa T, Sasako M, Terashima M. Yamada Y, et al. Among authors: iwasa s. Lancet Gastroenterol Hepatol. 2019 Jul;4(7):501-510. doi: 10.1016/S2468-1253(19)30083-4. Epub 2019 May 14. Lancet Gastroenterol Hepatol. 2019. PMID: 31101534 Clinical Trial.
407 results